Phase 2 trial of nivolumab in metastatic rare cancer with dMMR or MSI-H and relation with immune phenotypic analysis (the ROCK trial).

Hitomi Sumiyoshi Okuma Keisuke Watanabe Kenji Tsuchihashi Ryunosuke Machida Ryo Sadachi Akihiro Hirakawa Hiroshi Ariyama Masashi Kanai Masahisa Kamikura Kenta Anjo Akari Hiramitsu Shigeki Sekine Natsuko Okita Hiroyuki Mano Hiroyoshi Nishikawa Kenichi Nakamura Kan Yonemori

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The trial met its primary endpoint with nivolumab, demonstrating clinical benefit in advanced dMMR/MSI-H rare solid cancers. Besides, the proportion of T-bet+PD-1+ CD4+ T-cells may serve as a novel predictive biomarker.

Keyphrases

phase iii
study protocol
phase ii
clinical trial
papillary thyroid
squamous cell carcinoma
small cell lung cancer
tyrosine kinase
squamous cell
open label
young adults
lymph node metastasis
double blind